University of Colorado, Denver
cuanschutz.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,520
Active
371
Phase 3
49
Total enrollment
2,362,498
Pipeline matrix
Showing 40 of 151 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Montelukast | — | — | — | 4 | |||
| Pravastatin | — | — | — | — | 3 | ||
| Etonogestrel implant | — | — | — | — | — | 2 | |
| Omalizumab | — | — | — | — | — | 2 | |
| Vericiguat | — | — | — | — | — | 1 | |
| Efgartigimod | — | — | — | — | — | 1 | |
| Omeprazole 20mg BID | — | — | — | — | — | 1 | |
| Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum | — | — | — | — | — | 1 | |
| Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum | — | — | — | — | — | 1 | |
| Levonorgestrel/ethinyl estradiol | — | — | — | — | — | 1 | |
| NSAIDs | — | — | — | — | — | 1 | |
| Ozanimod | — | — | — | — | — | 1 | |
| Faricimab | — | — | — | — | — | 1 | |
| sham treatment | — | — | — | — | — | 1 | |
| Dapagliflozin 10mg Tab | — | — | — | — | — | 1 | |
| Ocrelizumab at home | — | — | — | — | — | 1 | |
| fenfluramine | — | — | — | — | — | 1 | |
| Methazolamide 25 MG | — | — | — | — | — | 1 | |
| Methazolamide 50 MG | — | — | — | — | — | 1 | |
| Sodium bicarbonate | — | — | — | 6 | |||
| GnRH antagonist | — | — | — | — | 3 | ||
| Degarelix | — | — | — | 3 | |||
| Dalbavancin | — | — | — | 3 | |||
| Transdermal estradiol patch | — | — | — | — | 2 | ||
| Transdermal placebo patch | — | — | — | — | 2 | ||
| Metformin | — | — | 7 | ||||
| Cannabidiol | — | — | — | — | 7 | ||
| Semaglutide | — | — | — | — | 2 | ||
| Shingrix | — | — | — | — | 2 | ||
| THC/CBD | — | — | — | — | — | 1 | |
| THC | — | — | — | — | — | 1 | |
| Anti-hypertensives | — | — | — | — | — | 1 | |
| Lipid Lowering Medication | — | — | — | — | — | 1 | |
| Fezolinetant | — | — | — | — | — | 1 | |
| Hormonal therapy | — | — | — | — | — | 1 | |
| Semaglutide Injectable Product | — | — | — | — | — | 1 | |
| Granisetron | — | — | — | — | — | 1 | |
| Palonosetron | — | — | — | — | — | 1 | |
| Essential Amino Acid Supplement by Amino Co | — | — | — | — | — | 1 | |
| Varenicline | — | — | — | — | — | 1 |
111 more active programs hidden
Next readouts
- 2021-08-31
- 2023-02-17
- 2023-06-30
- 2023-09-14
- 2023-12-11
- 2024-03-25
- 2024-05-26
- 2024-08
- 2024-08-06
- 2024-08-21
Top conditions
- Obesity70
- Type 1 Diabetes30
- Breast Cancer28
- Type 2 Diabetes23
- Aging20
- Diabetes18
- Parkinson Disease18
- Healthy17
Frequently asked questions about University of Colorado, Denver
- How many clinical trials does University of Colorado, Denver have on ClinicalTrials.gov?
- University of Colorado, Denver is listed as the lead sponsor on 1,520 clinical trials in ClinicalTrials.gov, 371 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Colorado, Denver's trials are in Phase 3?
- 49 of University of Colorado, Denver's trials are in Phase 3, spread across 151 active drug programs.
- What therapeutic areas does University of Colorado, Denver focus on?
- University of Colorado, Denver's most-studied conditions on ClinicalTrials.gov are Obesity, Type 1 Diabetes, Breast Cancer, Type 2 Diabetes, Aging.
- When are University of Colorado, Denver's next clinical trial readouts?
- University of Colorado, Denver has 10 upcoming primary-completion readouts tracked here; the soonest is “Home Based Infusions for Ocrelizumab”, expected around 2021-08-31.